18 completed, 7 terminated, 3 unknown, 1 withdrawn. 15 Phase 2, 7 Phase 1, 6 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 3 | 6 | Terminated 3, Completed 2, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow QLT Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT No treatment: retrospective chart review - Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP) | Completed | QLT Inc. | 59 | 2015-12-01 | 2016-04-29 | |
| Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation QLT091001, Placebo - Impaired Dark Adaptation | Phase 2 | Completed | QLT Inc. | 43 | 2013-11-01 | 2015-07-14 |
| Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) QLT091001 - Retinitis Pigmentosa (RP) | Phase 1 | Completed | QLT Inc. | 5 | 2012-02-01 | 2014-12-15 |
| Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) QLT091001 - LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa) | Phase 1 | Completed | QLT Inc. | 27 | 2012-01-01 | 2014-07-28 |
| A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG Latanoprost Punctal Plug Delivery System, Xalatan - Ocular Hypertension, Open-Angle Glaucoma | Phase 2 | Completed | Mati Therapeutics Inc. | 15 | 2009-12-01 | 2014-01-10 |
| A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China Candidiasis | Unknown | Southeast University, China | 300 | 2009-11-01 | 2010-12-06 | |
| Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations QLT091001 - LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa) | Phase 1 | Completed | QLT Inc. | 32 | 2009-11-01 | 2013-05-14 |
| A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS) Latanoprost - Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Mati Therapeutics Inc. | 32 | 2009-01-01 | 2013-09-19 |
| Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers QLT091001 - Healthy Human Volunteers | Phase 1 | Completed | QLT Inc. | 18 | 2008-09-01 | 2009-03-30 |
| Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) verteporfin, ranibizumab, dexamethasone - Choroidal Neovascularization, Macular Degeneration | Phase 2 | Completed | QLT Inc. | 162 | 2007-07-01 | 2011-06-02 |
| Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD reduced fluence photodynamic therapy with Visudyne, Lucentis - Age-Related Macular Degeneration | Not applicable | Unknown | Barnes Retina Institute | 30 | 2007-04-01 | 2008-05-09 |
| Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself Visudyne, Lucentis, Dexamethasone - Age Related Macular Degeneration | Phase 2 | Withdrawn | Vitreous -Retina- Macula Consultants of New York | 2007-01-01 | 2017-08-23 | |
| TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF) - Age-Related Macular Degeneration | Phase 2 | Terminated | National Eye Institute (NEI) | 100 | 2007-01-01 | 2010-03-24 |
| Combination Therapy for Age-Related Macular Degeneration. Avastin (Bevacizumab), Bevacizumab - Age Related Macular Degeneration | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 103 | 2006-09-01 | 2011-09-28 |
| Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Verteporfin Therapy/ Drug: Bevacizumab - Macular Degeneration | Phase 1 | Terminated | Vitreous -Retina- Macula Consultants of New York | 10 | 2006-09-01 | 2008-07-30 |
| A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis GHRP-1/AG 70 mg depot in ESRD, Placebo - End Stage Renal Disease | Phase 2 | Terminated | QLT Inc. | 3 | 2006-09-01 | 2011-04-04 |
| Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration ranibizumab, dexamethasone and verteporfin, Ranibizumab - Age Related Macular Degeneration | Phase 2 | Completed | Bay Area Retina Associates | 60 | 2006-08-01 | 2010-05-27 |
| A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide - Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2005-09-01 | 2016-03-31 |
| Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS) Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system - Prostatic Hyperplasia | Phase 2 | Terminated | QLT Inc. | 180 | 2005-05-01 | 2006-10-03 |
| Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD. Triamcinolone Acetonide - Age-Related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Canadian Retinal Trials Group | 120 | 2004-01-01 | 2007-07-30 |
Showing 20 of 29. Sign in to see all of them.
Macular Degeneration (12) · Choroidal Neovascularization (4) · Retinitis Pigmentosa (4) · Leber Congenital Amaurosis (3) · Carcinoma, Non-Small-Cell Lung (2) · Glaucoma, Open-Angle (2) · Ocular Hypertension (2) · Prostatic Hyperplasia (2) · Basal Cell Nevus Syndrome (1) · Basal cell carcinoma, multiple (1) · Breast Neoplasms (1) · Candidiasis (1) · Carcinoma, Basal Cell (1) · Glaucoma (1) · Kidney Failure, Chronic (1)
Verteporfin (9) · retinol acetate (5) · Ranibizumab (4) · Dexamethasone (3) · Drug Therapy (3) · Injections (3) · Photochemotherapy (3) · Triamcinolone Acetonide (3) · Bevacizumab (2) · Latanoprost (2) · tariquidar (2) · Carboplatin (1) · Paclitaxel (1) · QLT0074 (1) · Triamcinolone (1)
United States (18) · Canada (11) · Germany (3) · Netherlands (3) · United Kingdom (3) · Switzerland (2) · China (1) · Denmark (1) · Ireland (1)
Sushanta Mallick (3) · Graeme R Boniface (2) · Oscar Cuzanni, MD, MSc (2) · Allen Ho, MD (1) · Andrew Strong, Ph.D (1) · Andrew Strong, Ph.D. (1) · David A Maberley, M.D. (1) · David Saperstein, MD (1) · Gaurav K. Shah, MD (1) · Graeme Boniface, PhD (1) · Graeme R. Boniface, PhD (1) · Henry Hudson, MD (1) · Herma Neyndorff (1) · Jason S Slakter, M.D. (1) · Joel Naor, MD (1)
PMID 19530976, PMID 19748675, PMID 23543609, PMID 25030840, PMID 26448901, PMID 26656277, PMID 28114898, PMID 32573764